SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors digest news of its upcoming Russell 3000 index inclusion and a high-profile partnership with the U.S. Army to develop domestic heavy rare earth processing facilities. While the community is actively debating the company's long-term potential as a defense industry supplier versus concerns over volatility and dilution, traders are closely watching for signs of a short squeeze amid high short interest and institutional accumulation.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh strong quarterly profitability and upgraded analyst outlooks against geopolitical instability and Middle East shipping disruptions. The community remains focused on the company's long-term production growth and institutional backing, while actively debating the impact of energy sector volatility on its current valuation.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors debate the impact of high short interest and institutional manipulation against the brand's long-term growth potential and distribution partnership with Pepsi. The community is actively discussing the stock's recent volatility, comparing its performance to competitors like Monster, and speculating on the potential for a massive squeeze or buyout.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is seeing heightened investor attention as community members debate the timing of clinical trial catalysts and the potential for a strategic partnership, while some traders closely monitor the company's pending financial filings and ongoing volatility. Enthusiasts are focusing on the company's recent operational updates and the broader implications of its immunotherapy trial, while others remain cautious and continue to analyze the stock's tight float and the impact of short-selling pressure.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav is trending as shareholders anticipate an upcoming FCC Notice of Proposed Rulemaking (NPRM) regarding the company's spectrum rights, with active community discussion centered on potential national security catalysts and the impact of significant liquidity events like warrant redemptions. Investors are debating the timing of FCC agenda announcements and the influence of heavy institutional positioning against a backdrop of ongoing regulatory hurdles.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors prepare for an upcoming FDA advisory committee meeting and PDUFA date for its Duchenne muscular dystrophy therapy, Deramiocel. The stock faces volatility driven by community debate over the strength of clinical data, patent litigation, and institutional accumulation, with bulls emphasizing strong Phase 3 results as the primary catalyst for a potential rally.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant downward pressure as investors navigate the recent integration of TopBuild and lingering concerns over share dilution, while the community remains divided between long-term bulls betting on Brad Jacobs' track record and frustrated traders wary of continued selling. The stock is a focal point of intense discussion as market participants debate whether the current price action represents a forced liquidation by arbitrageurs or a more fundamental long-term challenge.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is seeing extreme volatility as market participants debate whether recent massive pullbacks represent a genuine buying opportunity or a deeper correction fueled by institutional liquidation. The stock remains a focal point for intense sentiment clashes, with traders divided between betting on a sharp relief bounce and warning of further downside pressure amid broader semiconductor sector jitters.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending as investors reassess the company's growth trajectory following a significant stock price pullback. While the company continues to demonstrate strong fundamentals and a dominant market position, the community is debating whether the current price action reflects a temporary valuation reset or a long-term shift in growth expectations.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is trending due to a surge in investor confidence driven by rebounding lithium prices, strong demand for battery energy storage, and strategic supply chain shifts. The community is actively discussing its momentum, with many highlighting potential breakouts and long-term recovery prospects as the company benefits from both increased EV adoption and energy infrastructure needs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

Key PointsSamira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000...

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

Key Points15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share...

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Societys...

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +63.04% and +32.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates

Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +54.76% and +22.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -510.13% and -94.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of -48.03% and +1.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Septerna (NASDAQ:SEPN) Now Covered by Stifel Nicolaus

Stifel Nicolaus initiated coverage on Septerna in a research note on Friday. They set a "buy" rating and a $43.00 price objective on the stock...

Septerna, Inc. (NASDAQ:SEPN) Sees Significant Growth in Short Interest

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 2,457,303 shares, a growth of 12.9...

Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN - Get Free Report) have earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, s...

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Septerna Inc.

Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$33.40
Prev Close	$31.56
Open	$30.98
Dividend Yield	0.00%
50-Day Moving Average	$31.44
Beta	1.30
Avg. Volume	469,567.27
PE Ratio	-38.63

52-Week High	$38.04
52-Week Low	$10.62
Market Capitalization	$1.42B
EPS (Annual)	-$1.10
Price to Book	3.75
Revenue Per Employee	$353,469.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

SEPNSepterna Inc.

Latest SEPN News